


I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office, Fax No. 1-571-273-8300 on August 15, 2005.

TOWNSEND and TOWNSEND and CREW LLP

By: 

**AMENDMENT AND REPLY UNDER
37 C.F.R. § 1.114 (RCE)**

PATENT

Attorney Docket No.: 022052-000700US

**RECEIVED
CENTRAL FAX CENTER**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

AUG 15 2005

In re application of:

Beverly Lynn Mangold, et al.

Application No.: 09/844,281

Filed: April 30, 2001

For: ANTHRAX SPECIFIC
ANTIBODIES

Customer No.: 20350

Confirmation No. 1022

Examiner: Jennifer E. Graser

Technology Center/Art Unit: 1645

**AMENDMENT AND REPLY UNDER 37
C.F.R. § 1.114 (RCE)**

Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This is in response to the "final" Office Action mailed November 5, 2004, which set February 5, 2005 as the initial period for response. As set forth in the accompanying Petition For Revival of an Application under 37 CFR 1.137(b), Applicants unintentionally failed to respond to the Action. Accordingly, this Amendment and Reply responds to the Action as part of the accompanying Request for Continued Examination.

Please amend the above-identified U.S. patent application as follows.

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks/Arguments begin on page 5 of this paper.

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application: